JP2002507579A - 脳組織障害の予防および治療用システインプロテアーゼインヒビター含有医薬組成物 - Google Patents

脳組織障害の予防および治療用システインプロテアーゼインヒビター含有医薬組成物

Info

Publication number
JP2002507579A
JP2002507579A JP2000537569A JP2000537569A JP2002507579A JP 2002507579 A JP2002507579 A JP 2002507579A JP 2000537569 A JP2000537569 A JP 2000537569A JP 2000537569 A JP2000537569 A JP 2000537569A JP 2002507579 A JP2002507579 A JP 2002507579A
Authority
JP
Japan
Prior art keywords
formula
group
carbon atoms
composition according
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2000537569A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002507579A5 (enExample
Inventor
光佳 東
征夫 吉田
雄二 坂本
淳 井上
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Publication of JP2002507579A publication Critical patent/JP2002507579A/ja
Publication of JP2002507579A5 publication Critical patent/JP2002507579A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2000537569A 1998-03-20 1999-03-17 脳組織障害の予防および治療用システインプロテアーゼインヒビター含有医薬組成物 Ceased JP2002507579A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP10-72280 1998-03-20
JP7228098 1998-03-20
PCT/JP1999/001335 WO1999048522A1 (en) 1998-03-20 1999-03-17 Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment

Publications (2)

Publication Number Publication Date
JP2002507579A true JP2002507579A (ja) 2002-03-12
JP2002507579A5 JP2002507579A5 (enExample) 2006-03-23

Family

ID=13484725

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000537569A Ceased JP2002507579A (ja) 1998-03-20 1999-03-17 脳組織障害の予防および治療用システインプロテアーゼインヒビター含有医薬組成物

Country Status (19)

Country Link
US (1) US6342531B1 (enExample)
EP (1) EP1064021B1 (enExample)
JP (1) JP2002507579A (enExample)
KR (1) KR20010041967A (enExample)
CN (1) CN1301173A (enExample)
AR (1) AR018784A1 (enExample)
AT (1) ATE275420T1 (enExample)
AU (1) AU2852699A (enExample)
BR (1) BR9908948A (enExample)
CA (1) CA2324566A1 (enExample)
DE (1) DE69919995T2 (enExample)
ES (1) ES2224613T3 (enExample)
HU (1) HUP0101428A2 (enExample)
ID (1) ID27507A (enExample)
MX (1) MXPA00009188A (enExample)
MY (1) MY133063A (enExample)
NO (1) NO20004679L (enExample)
PL (1) PL342970A1 (enExample)
WO (1) WO1999048522A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7766300A (en) * 1999-10-07 2001-05-10 Novaneuron Inc. Gene necessary for striatal function, uses thereof, and compounds for modulatingsame
JPWO2002034252A1 (ja) 2000-10-26 2004-03-04 千寿製薬株式会社 ジペプチジルアルデヒド誘導体含有医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011850A2 (en) 1990-12-28 1992-07-23 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
ATE239698T1 (de) 1995-10-25 2003-05-15 Senju Pharma Co Angiogenese hemmer

Also Published As

Publication number Publication date
PL342970A1 (en) 2001-07-16
MXPA00009188A (es) 2002-04-24
EP1064021B1 (en) 2004-09-08
ES2224613T3 (es) 2005-03-01
ID27507A (id) 2001-04-12
KR20010041967A (ko) 2001-05-25
NO20004679D0 (no) 2000-09-19
ATE275420T1 (de) 2004-09-15
DE69919995D1 (de) 2004-10-14
DE69919995T2 (de) 2005-09-22
US6342531B1 (en) 2002-01-29
AR018784A1 (es) 2001-12-12
BR9908948A (pt) 2000-11-21
MY133063A (en) 2007-10-31
WO1999048522A1 (en) 1999-09-30
NO20004679L (no) 2000-10-26
CA2324566A1 (en) 1999-09-30
EP1064021A1 (en) 2001-01-03
CN1301173A (zh) 2001-06-27
AU2852699A (en) 1999-10-18
HUP0101428A2 (hu) 2001-09-28

Similar Documents

Publication Publication Date Title
JP2002539257A (ja) 薬剤の脳内生物学的利用率の増加
RU2262933C2 (ru) Медицинские композиции, содержащие аспирин
HU215922B (hu) 1-[(4-Karbazolil)-oxi]-3-amino-2-propanol-származékok alkalmazása simaizomsejt-burjánzás gátlására szolgáló gyógyszerkészítmények előállítására
SK110598A3 (en) Pharmaceutical composition containing an association of active principles, use of said composition for the preparation of a medicament and treatment method of disease induced by blood platelet aggregation
EP2786750B2 (en) Agent for reducing adverse side effects of kinase inhibitor
JP2002537258A5 (enExample)
KR101516677B1 (ko) 지방성 간 질환의 치료용 의약 조성물
JPH01153689A (ja) 抗パーキンソン病エルゴリン誘導体
JPH08503710A (ja) ヒドロキシカルバゾール化合物の抗酸化心臓保護的使用およびそれを使用する治療方法
KR20200054910A (ko) 젬카빈, 이의 약학적으로 허용 가능한 염, 조성물 및 이의 사용 방법
KR19990008341A (ko) 뇌부종 억제제
JP4874482B2 (ja) アスピリンを含有する医薬組成物
US20220168385A1 (en) Use of cyclosporine analogues as antithrombotic agents
JPH01211522A (ja) 梗塞および急性脳虚血の予防薬
EP1064021B1 (en) Use of cysteinprotease inhibitors for the manufacture of a medicament for prevention and treatment of brain tissue impairment due to hypertensive encephalopathy or encephalothlipsis.
JPH0680569A (ja) 血小板凝集阻害剤
WO2016206576A1 (zh) 一种氘代噻吩并哌啶衍生物、制备方法及其应用
JPH07228543A (ja) β３−アドレナリン作動薬の新規医薬用途
JP2665564B2 (ja) 細胞防護剤
JP2893903B2 (ja) 虚血―再灌流障害予防、治療剤
RU2007169C1 (ru) Средство, обладающее антигипертензивным действием
JPH0410446B2 (enExample)
JPS63218622A (ja) 虚血性心疾患の治療・予防剤
TW202504579A (zh) 肝臟疾病患者之內臟血管擴張的治療
JP3845307B2 (ja) 心筋梗塞治療薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090911

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100415

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20121127